This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

reputable news agency

proofread

CAR T-cell therapy appears to be feasible, safe for autoimmune diseases

CAR T-cell therapy feasible, safe for autoimmune diseases

CD19 chimeric antigen receptor (CAR) T-cell therapy seems feasible, safe, and efficacious for patients with different autoimmune diseases, according to a study published in the Feb. 22 issue of the New England Journal of Medicine.

Fabian Müller, M.D., from the Friedrich-Alexander University Erlangen-Nürnberg in Germany, and colleagues examined patients with severe systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, or systemic sclerosis (eight, three, and four patients, respectively) who received a single infusion of CD19 CAR T-cells after fludarabine and cyclophosphamide preconditioning.

Efficacy was assessed up to two years after CAR T-cell infusion, measured using the Definition of Remission in SLE (DORIS) criteria, American College of Rheumatology-European League against Rheumatism (ACR-EULAR) major clinical response, and the score on the European Scleroderma Trials and Research Group (EUSTAR) activity index.

Patients were followed for a median of 15 months. The mean duration of B-cell aplasia was 112 ± 47 days. The researchers found that all patients with SLE had DORIS remission, all patients with idiopathic inflammatory myositis had an ACR-EULAR major clinical response, and a reduction in the score on the EUSTAR activity index was seen for all patients with . In all patients, immunosuppressive therapy was completely stopped. In 10 patients, grade 1 cytokine release syndrome occurred.

"Even though it is premature to judge whether these patients are indeed cured from their autoimmune disease, CD19 CAR T-cells at least appear to be able to achieve sustained disease- and drug-free remission," the authors write.

More information: Fabian Müller et al, CD19 CAR T-Cell Therapy in Autoimmune Disease—A Case Series with Follow-up, New England Journal of Medicine (2024). DOI: 10.1056/NEJMoa2308917

John D. Isaacs, CAR T Cells—A New Horizon for Autoimmunity?, New England Journal of Medicine (2024). DOI: 10.1056/NEJMe2400203

Journal information: New England Journal of Medicine

Copyright © 2024 HealthDay. All rights reserved.

Citation: CAR T-cell therapy appears to be feasible, safe for autoimmune diseases (2024, February 22) retrieved 24 April 2024 from https://medicalxpress.com/news/2024-02-car-cell-therapy-feasible-safe.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

CAR-T cell therapy leads to long-term remission in lupus while maintaining vaccine response

40 shares

Feedback to editors